These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21401887)

  • 1. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target.
    Fontana V; Silva PS; Belo VA; Antonio RC; Ceron CS; Biagi C; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):130-7. PubMed ID: 21401887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
    Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
    Cheng X; Zhou Q; Lin S; Wu R
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Oct; 35(10):1048-56. PubMed ID: 21051829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats.
    Lu J; Hao J; Du H; Xiao B; Li Y; Yang X; Cui W
    Cell Physiol Biochem; 2016; 39(1):47-60. PubMed ID: 27322513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
    Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
    Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinases in patients with Wegener's granulomatosis.
    Bjerkeli V; Halvorsen B; Damås JK; Nordøy I; Yndestad A; Aukrust P; Frøland SS
    Ann Rheum Dis; 2004 Dec; 63(12):1659-63. PubMed ID: 15547092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis.
    Rautelin HI; Oksanen AM; Veijola LI; Sipponen PI; Tervahartiala TI; Sorsa TA; Lauhio A
    Ann Med; 2009; 41(3):208-15. PubMed ID: 18979291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
    Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
    Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.
    Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF
    Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
    Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
    J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in hypertension-induced renal damage.
    Hultström M; Leh S; Skogstrand T; Iversen BM
    Nephrol Dial Transplant; 2008 Mar; 23(3):896-903. PubMed ID: 17977875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term MMP inhibition by doxycycline exerts divergent effect on ventricular extracellular matrix deposition and systolic performance in stroke-prone spontaneously hypertensive rats.
    Zeng S; Zhou X; Tu Y; Yao M; Han ZQ; Gao F; Li YM
    Clin Exp Hypertens; 2011; 33(5):316-24. PubMed ID: 21649529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
    Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
    Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.